Gefitinib (Iressa®) in metastatic patients with non-small cell lung cancer
preliminary experience in a Brazilian center
Keywords:
Lung neoplasms, Epidermal growth factor receptor, Administration & dosage, Adverse effects, Prospective studiesAbstract
CONTEXT: Patients with metastatic non-small cell lung cancer are deemed incurable, but they may derive some benefit from systemic palliative chemotherapy. Recently, with the introduction of epidermal growth factor receptor (EGFR) antagonists such as gefitinib (Iressa®), an effective and less toxic option is now available for the treatment of such patients. OBJECTIVE: To assess the activity and toxicity of gefitinib in a group of Brazilian patients. TYPE OF STUDY: Prospective, open label, nonrandomized and non-controlled. SETTING: Clínica de Oncologia e Hematologia (CLIOH), São Paulo, Brazil. PATIENTS AND METHODS: From June 2002 to April 2003 we treated five patients with metastatic previously-treated non-small cell lung cancer (median of two previous chemotherapy regimens), using gefitinib at a dose of 250 mg orally on a daily basis, within a compassionate protocol sponsored by AstraZeneca. The patients’ median age was 65 years and two of them were male. Three had a performance status of 1, one of 2 and one of 3, on the ECOG (Eastern Cooperative Oncology Group) scale. RESULTS: We observed skin rash in two patients, diarrhea in three and arthralgia in two. One patient had a partial response and another had stabilization of her disease, as measured via imaging studies (which have lasted for more than 11 and 4 months, respectively), which were accompanied by significant decrease in tumor markers, whereas three patients worsened during treatment. DISCUSSION: New options of chemotherapy agents with favorable toxicity profiles are urgently needed for the treatment of metastatic non-small lung cancer patients who usually have short life expectancies. In our small series of five patients, we observed stabilization of the disease in two of them and the skin and gastrointestinal reactions often described in the literature in all of them. Two had arthralgia, not reported before. CONCLUSION: We concluded that gefitinib is an important addition to the therapeutic armamentarium for patients with metastatic non-small cell lung cancer.
Downloads
References
Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs. 2002;11(6):837-49.
Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine
kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003;14(6):922-30.
Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003;30(1 Suppl 1):30-8.
LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine ki- nase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003;9(6):2040-8.
